Tokio Marine Asset Management Co. Ltd. Raises Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,575 shares of the biopharmaceutical company’s stock after buying an additional 195 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $684,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $52,000. Duality Advisers LP increased its holdings in shares of Alnylam Pharmaceuticals by 81.5% in the 4th quarter. Duality Advisers LP now owns 17,112 shares of the biopharmaceutical company’s stock valued at $3,275,000 after acquiring an additional 7,682 shares during the period. EFG Asset Management Americas Corp. increased its holdings in shares of Alnylam Pharmaceuticals by 5.1% in the 4th quarter. EFG Asset Management Americas Corp. now owns 16,251 shares of the biopharmaceutical company’s stock valued at $3,111,000 after acquiring an additional 794 shares during the period. Lindbrook Capital LLC increased its holdings in shares of Alnylam Pharmaceuticals by 37.2% in the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 100 shares during the period. Finally, abrdn plc increased its holdings in shares of Alnylam Pharmaceuticals by 910.7% in the 4th quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock valued at $44,544,000 after acquiring an additional 209,691 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Chardan Capital cut their target price on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, February 16th. Citigroup dropped their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, April 21st. BMO Capital Markets reissued an “outperform” rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. Eight equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $215.88.

Alnylam Pharmaceuticals Trading Down 0.3 %

NASDAQ:ALNY opened at $143.31 on Friday. The firm has a market cap of $18.05 billion, a price-to-earnings ratio of -40.26 and a beta of 0.39. The company’s 50-day moving average is $150.29 and its two-hundred day moving average is $165.97. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the company posted ($1.68) earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.